Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EBITDA (2016 - 2025)

Arcadia Biosciences' EBITDA history spans 12 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 39.67% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$2.5 million, up 31.51%, while the annual FY2025 figure was -$2.5 million, 31.47% up from the prior year.
  • EBITDA reached -$1.4 million in Q4 2025 per RKDA's latest filing, down from -$1.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.1 million in Q1 2021 to a low of -$9.3 million in Q4 2021.
  • Average EBITDA over 5 years is -$2.1 million, with a median of -$1.7 million recorded in 2024.
  • Peak YoY movement for EBITDA: plummeted 324.64% in 2022, then soared 134.6% in 2024.
  • A 5-year view of EBITDA shows it stood at -$9.3 million in 2021, then soared by 54.16% to -$4.2 million in 2022, then soared by 71.89% to -$1.2 million in 2023, then crashed by 91.03% to -$2.3 million in 2024, then soared by 39.67% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EBITDA are -$1.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$501000.0 (Q2 2025).